Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), the Lancet reports
March 31st, 2009
Data published online and in an upcoming print issue of The Lancet show that Gleevec(R) (imatinib mesylate) tablets*, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo. The Phase III study published was led by the American College of Surgeons Oncology Group (ACOSOG) and examined post-surgery, or adjuvant, treatment of more than 700 GIST patients. Researchers found that 98% of patients receiving 400 mg of Gleevec daily remained tumor-free one year after surgery. The study also found Gleevec to be safe and well-tolerated, with a low rate of serious adverse events(1). ...
Source: Cancer Weekly (2009-03-31)
|
